BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel.
Metrics to compare | PHGE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHGEPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.7x | −2.7x | −0.6x | |
PEG Ratio | −0.01 | −0.06 | 0.00 | |
Price/Book | 25.7x | 1.5x | 2.6x | |
Price / LTM Sales | - | 11.1x | 3.3x | |
Upside (Analyst Target) | - | 687.2% | 38.0% | |
Fair Value Upside | Unlock | 3.8% | 4.3% | Unlock |